Sights set firmly on Canada as CPH completes Mernova purchase
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Creso Pharma Limited (ASX:CPH) has informed the market it has completed the acquisition of emerging Nova Scotia-based medicinal cannabis producer, Mernova Medicinal Inc (Mernova).
With the acquisition now finalised, the development marks CPH’s formal entry into Canada — making it the only Australian cannabis company with direct exposure to the world’s largest legal medical cannabis market.
With the completed acquisition, CPH also makes good on its strategy of establishing a Canadian presence and its pursuit of opportunities in the medicinal cannabis space. Further, by entering the Canadian market, the company gains exposure to the country’s considerable recreational cannabis market once this is legalised, with legalisation expected in mid-2018.
However, how much of the market CPH is able to corner is speculative at this stage and therefore investors shouldn’t act on this fact alone, but should take all publicly available information into account and seek professional financial advice.
Following tax advice, the company has finalised the acquisition through two newly incorporated Canadian subsidiaries: Creso Canada Limited and Creso Canada Corporate Limited. As a result of the transaction, Mernova shareholders were paid a cash payment of C$200,000 (AU$201,180) and issued a total of 8,300,000 exchangeable shares in Creso Canada Limited. These shares are exchangeable for fully paid ordinary shares in CPH, upon the satisfaction of certain milestones.
Further details relating to the Mernova acquisition can be found in CPH’s 13 February announcement and in a recent Finfeed article.
A week ago, CPH announced its progress in leveraging another thriving cannabis market —Colombia, which it looks to enter via its recently proposed acquisition of Kunna Canada Ltd.
Kunna has a licence to produce, manufacture, market and export cannabis derivatives and products using extracts in Colombia by the Ministry of Health, making it one of a small number of companies to have secured such a licence. Kunna anticipates receiving its licence to cultivate medicinal cannabis in Colombia in April.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
